vitamin-d-2 has been researched along with Atrophy* in 3 studies
1 trial(s) available for vitamin-d-2 and Atrophy
Article | Year |
---|---|
Effect of Vitamin D Supplement on Vulvovaginal Atrophy of the Menopause.
The effects of oral vitamin D supplements on vaginal health in postmenopausal women with vulvovaginal atrophy (VVA) was evaluated. A double-blinded, randomized placebo-controlled trial was conducted for 12 weeks to investigate changes on vaginal maturation index (VMI), vaginal pH, and the visual analog scale (VAS) of VVA symptoms. The vitamin D group received oral ergocalciferol, at 40,000 IU per week, while the placebo group received an identical placebo capsule. Eighty postmenopausal women were enrolled. There were no significant differences in baseline characteristics between both groups. In an intention-to-treat analysis, VMI, vaginal pH, and VAS of VVA symptoms showed no significant differences between both groups at the six and 12 weeks. However, the mean difference of VMI in the vitamin D group between baseline and at six weeks showed significant improvement (5.5 + 16.27, Topics: Atrophy; Dietary Supplements; Double-Blind Method; Ergocalciferols; Female; Humans; Menopause; Middle Aged; Postmenopause; Vagina; Vitamins | 2020 |
2 other study(ies) available for vitamin-d-2 and Atrophy
Article | Year |
---|---|
Paricalcitol prevents cisplatin-induced renal injury by suppressing apoptosis and proliferation.
The present study was performed to examine whether paricalcitol may prevent the cisplatin-induced kidney injury. Furthermore, potential molecular mechanisms underlying the protective effect of paricalcitol were explored. Male Sprague-Dawley rats were treated with vehicle (n=12), cisplatin (n=12, 6 mg/kg/day, i.p.), or cisplatin+paricalcitol (n=12, 0.2 μg/kg/day, s.c.) for 4 days. In another series of experiment, HK-2 cells were treated with cisplatin (50 μM), with or without paricalcitol (0.2 ng/ml). Paricalcitol counteracted the cisplatin-induced decline in renal function. Paricalcitol also suppressed the expression of TGF-β1, Smad signaling, and the subsequent epithelial-to-mesenchymal process in cisplatin-treated rats. The expression of P-p53 and p21 was increased in cisplatin-induced nephropathy. These changes were completely prevented or significantly attenuated with paricalcitol co-treatment. The expression of p27(kip1) was increased in cisplatin-treated rats, which was, however, further augmented by the paricalcitol co-treatment. In HK-2 cells, cisplatin increased the expression of p-ERK1/2 and P-p38. Cisplatin also increased the expression of fibronectin and CTGF. Cisplatin increased the expression of pro-apoptotic markers. The expression of CDK2 and Cyclin E as well as that of PCNA was increased. These changes were completely prevented or significantly attenuated by the paricalcitol pretreatment. In contrast, cisplatin increased the expression of p27(kip1), which was further augmented by the paricalcitol-pretreatment. These results suggest that paricalcitol may ameliorate cisplatin-induced renal injury by suppressing the fibrotic, apoptotic and proliferative factors. Its underlying mechanisms may include inhibition of TGF-β1, mitogen-activated protein kinase signaling, p53-induced apoptosis, and augmentation of p27(kip1). Topics: Acute Kidney Injury; Animals; Antineoplastic Agents; Apoptosis; Atrophy; Bone Density Conservation Agents; Cell Line; Cell Proliferation; Cisplatin; Cyclin-Dependent Kinase Inhibitor p27; Ergocalciferols; Humans; Kidney; Male; MAP Kinase Signaling System; Protective Agents; Rats; Rats, Sprague-Dawley; Transforming Growth Factor beta1; Tumor Suppressor Protein p53 | 2012 |
[Chloramphenicol, vitamin D2 and dihydrofolliculin in therapy of atrophic catarrhal rhinitis and ozena].
Topics: Atrophy; Chloramphenicol; Cholestanes; Common Cold; Ergocalciferols; Estrogens; Humans; Rhinitis; Rhinitis, Atrophic; Vitamin D; Vitamins | 1953 |